Literature DB >> 8765105

Drug-drug and drug-disease interactions in the ED: analysis of a high-risk population.

R M Goldberg1, J Mabee, L Chan, S Wong.   

Abstract

A study was undertaken to determine the potential for adverse drug interactions (ADIs) and drug-disease interactions (DDIs) in a high-risk population of emergency department (ED) patients and to characterize drug-drug and drug-disease interactions in terms of percentage of patients at risk from existing drug regimens, percentage of patients at risk from ED treatment, relation between number of drugs and potential for interactions, types of drugs and diseases posing greatest potential for interaction, and the differences in a general versus community hospital population with respect to these parameters. Records of 205 consecutive patients, 111 from a general hospital teaching facility ED (Facility 1) and 94 from a community hospital ED (Facility 2) were retrospectively reviewed. The records of all patients receiving three or more medications and all patients older than 50 years of age receiving two or more medications were analyzed by two computer programs for the presence of potential drug-drug and drug-disease interactions. A total of 226 potential ADIs were found in 89 patients (47%), with 50% of ADIs being related to ED treatment. A total of 94 potential DDIs were found in 44 patients (21%), with 34% of DDIs being related to ED treatment. The risk of an ADI rose from 13% for patients taking 2 medications to 82% for patients taking 7 or more medications. Eleven medications and four disease categories were identified as having particular potential for interactions. No significant differences were found between the general and the community hospital populations in these respects. ED patients taking three or more medications and patients older than 50 years of age taking two or more medications are at substantial risk for adverse drug-drug and drug-disease interactions. The risk is increased in patients taking particular drugs or having particular disease states.

Entities:  

Mesh:

Year:  1996        PMID: 8765105     DOI: 10.1016/S0735-6757(96)90147-3

Source DB:  PubMed          Journal:  Am J Emerg Med        ISSN: 0735-6757            Impact factor:   2.469


  79 in total

1.  The incidence of potential drug-drug interactions in elderly patients with arterial hypertension.

Authors:  Vesna Bacic-Vrca; Srecko Marusic; Viktorija Erdeljic; Slaven Falamic; Nives Gojo-Tomic; Dario Rahelic
Journal:  Pharm World Sci       Date:  2010-10-05

2.  A conceptual framework for evaluating outpatient electronic prescribing systems based on their functional capabilities.

Authors:  Douglas S Bell; Shan Cretin; Richard S Marken; Adam B Landman
Journal:  J Am Med Inform Assoc       Date:  2003-10-05       Impact factor: 4.497

Review 3.  Initiation of statin therapy: are there age limits?

Authors:  Dipan A Desai; Sammy Zakaria; Pamela Ouyang
Journal:  Curr Atheroscler Rep       Date:  2012-02       Impact factor: 5.113

Review 4.  Adverse drug reactions in older people: detection and prevention.

Authors:  Mirko Petrovic; Tischa van der Cammen; Graziano Onder
Journal:  Drugs Aging       Date:  2012-06-01       Impact factor: 3.923

Review 5.  Predicting risk of adverse drug reactions in older adults.

Authors:  Amanda Hanora Lavan; Paul Gallagher
Journal:  Ther Adv Drug Saf       Date:  2016-02

6.  Quality indicators for in-hospital pharmaceutical care of Dutch elderly patients: development and validation of an ACOVE-based quality indicator set.

Authors:  Peter C Wierenga; Joanna E Klopotowska; Susanne M Smorenburg; Hendrikus J van Kan; Yuma A Bijleveld; Marcel G Dijkgraaf; Sophia E de Rooij
Journal:  Drugs Aging       Date:  2011-04-01       Impact factor: 3.923

Review 7.  Managing comorbidities in patients at the end of life.

Authors:  James Stevenson; Amy P Abernethy; Cathy Miller; David C Currow
Journal:  BMJ       Date:  2004-10-16

Review 8.  Granisetron in the control of radiotherapy-induced nausea and vomiting: a comparison with other antiemetic therapies.

Authors:  Petra Feyer; M Heinrich Seegenschmiedt; Maria Steingraeber
Journal:  Support Care Cancer       Date:  2005-07-26       Impact factor: 3.603

9.  Absolute contraindications in relation to potential drug interactions in outpatient prescriptions: analysis of the first five million prescriptions in 1999.

Authors:  Laurence Guédon-Moreau; Dominique Ducrocq; Marie-Francoise Duc; Yves Quieureux; Catherine L'Hôte; Jean Deligne; Jacques Caron
Journal:  Eur J Clin Pharmacol       Date:  2003-12-19       Impact factor: 2.953

10.  Absolute contraindications in relation to potential drug interactions in outpatient prescriptions: analysis of the first five million prescriptions in 1999.

Authors:  Laurence Guédon-Moreau; Dominique Ducrocq; Marie-Francoise Duc; Yves Quieureux; Catherine L'Hôte; Jean Deligne; Jacques Caron
Journal:  Eur J Clin Pharmacol       Date:  2003-10-14       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.